MARKET

BOLD

BOLD

BOUNDLESS BIO INC
NASDAQ
2.440
+0.030
+1.24%
After Hours: 2.470 +0.03 +1.23% 19:06 07/13 EDT
OPEN
2.420
PREV CLOSE
2.410
HIGH
2.480
LOW
2.350
VOLUME
308.11K
TURNOVER
--
52 WEEK HIGH
2.790
52 WEEK LOW
0.9612
MARKET CAP
54.84M
P/E (TTM)
-0.9755
1D
5D
1M
3M
1Y
5Y
1D
Tang Capital’s Kevin Tang reports $238,263 purchase of Boundless Bio common shares
PUBT · 42m ago
Weekly Report: what happened at BOLD last week (0706-0710)?
Weekly Report · 14h ago
Kevin Tang reports $141,464 purchase of 57,210 Boundless Bio common shares
PUBT · 4d ago
Major Investors Quietly Trim Stakes in Boundless Bio Inc. Amid Notable Trading Activity
TipRanks · 6d ago
ARCH Venture Fund IX disposes of 16,000 Boundless Bio common shares worth $39,840
PUBT · 07/06 21:44
Weekly Report: what happened at BOLD last week (0629-0703)?
Weekly Report · 07/06 09:11
Major Investor Doubles Down on Boundless Bio With Bold New Stock Purchase
TipRanks · 07/03 02:02
Boundless Bio 10% owner Kevin Tang reports $272,474 common share purchase
PUBT · 07/02 23:46
More
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

Webull offers Boundless Bio Inc stock information, including NASDAQ: BOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLD stock methods without spending real money on the virtual paper trading platform.